Jiangsu Recbio Technology Co., Ltd. risk profile
80 Acute at or past the historical limit
Measured 20 October 2026 from 2179.HK's filed statements. Recomputed nightly.
80 (Acute), driven by Cash conversion at 100, over 4 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 86 | Acute | Stable | Drawdown from the 52-week high — 50.0% |
| Operating pressure | Reads cost_of_revenue, operating_expense, operating_income and revenue. No reading is stored for this company. | |||
| Cash conversion | 100 | Acute | Stable | Capital spending against operating cash — -0.20x |
| Leverage and coverage | 95 | Acute | Stable | Net debt to EBITDA |
| Competitive position | 69 | Stretched | Stable | Operating-margin gap against peers — -4,606.4 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for Jiangsu Recbio Technology Co., Ltd.